Thrombin-induced platelet aggregation -effect of dabigatran using automated platelet aggregometry.

Thrombin-induced platelet aggregation -effect of dabigatran using automated platelet aggregometry. Platelets. 2019 Jun 04;:1-5 Authors: Shimizu M, Natori T, Tsuda K, Yoshida M, Kamada A, Oi K, Ishigaku Y, Oura K, Narumi S, Yamamoto M, Terayama Y Abstract Dabigatran, a direct oral thrombin inhibitor, has two therapeutic effects: anticoagulation; and antiplatelet activity. In the clinical field, evaluation of the effect of dabigatran on thrombin-induced platelet aggregation is difficult because of fibrin clot formation and platelet aggregation. The aim of this study was to establish a new platelet aggregation method and to investigate the effects of dabigatran on thrombin-induced platelet aggregation. Platelet aggregation with thrombin was performed with automated light transmission aggregometry (CS2400; Sysmex, Kobe, Japan) in 40 healthy subjects. Thrombin-induced platelet aggregation was performed using thrombin and platelet-rich plasma (PRP), and thrombin-induced fibrin polymerization was inhibited by adding the peptide Gly-Pro-Arg-Pro (GPRP). The effect of dabigatran was then evaluated using the above method. Thrombin at < 0.2 U/mL did not induce platelet aggregation in most normal subjects. Median maximum aggregation percent (MA%) (25th-75th percentile) with 0.5 and 1.0 U/mL of thrombin was 87.0% (79.3-90.8%), and 90.2% (86.5-92.2%), respectively. The anti-platelet effects of dabigatran were then evaluated with these concentr...
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research